Peter Vermeul’s Post
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchTHCCBDHempSafetyDosingNeurology Why This Matters Clinicians need to understand that cannabis effects depend on…
PleoPharma Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial
Cannabis withdrawal syndrome treatment is advancing with PleoPharma's Phase 3 trial of PP-01. This medication targets withdrawal symptoms that hinder recovery. The trial aims to improve treatment outcomes for cannabis use disorder.
TribeTokes Everything But The Kitchen Sink Gummies
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. SleepAnxietyMental HealthCBDTHCDosingSafety Clinical Summary This article appears to be marketing content for TribeTokes…
Review Finds Just 31% of Consumer CBD Products Meet Label-Accuracy Standard
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDSafetyIndustryResearchPolicyHempDosing Why This Matters Clinicians prescribing or recommending CBD to patients face a…
What’s in My Weed?
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyCBDTHCHempIndustryDosing Clinical Summary This article examines the results of laboratory testing for…
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyMental HealthAnxietyNeurologyDosingIndustry Why This Matters This Phase 3 trial represents the first…
What’s in your weed? Study finds issues with labelling, tracking cannabis
✦ New CED Clinical Relevance #50 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchSafetyIndustryTHCCBDDosing Why This Matters Clinicians need accurate product labeling and composition data…
When Back Pain Becomes Chronic: New Drug and Old-Fashioned Remedies Hold Promise
The standardized cannabis pharmaceutical offers a new regulated option for chronic back pain management. This product provides consistent dosing and quality control compared to herbal cannabis. It represents a promising alternative for patients with…
Headed to a New York Dispensary This Weekend? Silly Nice Launches Concentrate Education Hub
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. THCIndustrySafetyDosingResearchHempCBD Why This Matters Clinicians should understand cannabis concentrate potency…
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyDosingNeurologyAnxietyIndustry Why This Matters This pivotal Phase 3 trial represents the…